Drug intelligence / Profile preview

UMC119-01

Development stage: Phase 1
Lead developer: Meridigen Biotech
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intratracheal

Overview

UMC119-01 is an allogeneic cell therapy consisting of umbilical cord-derived mesenchymal stem cells (UC-MSCs), developed by Meridigen Biotech. It is primarily being investigated for the prevention and treatment of bronchopulmonary dysplasia (BPD) in premature infants at high risk for the condition. The therapeutic rationale is based on the immunomodulatory, anti-inflammatory, and regenerative properties of MSCs, which are thought to mitigate the lung injury caused by hyperoxia and mechanical ventilation. By secreting various paracrine factors, these cells help reduce pulmonary inflammation and promote the repair of alveolar and vascular structures in the developing neonatal lung.

Other names: umbilical cord-derived mesenchymal stem cellsUC-MSC

Beyond the preview

Go deeper on UMC119-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UMC119-01.

Explore the full profile